Ke Zhang

Dr. Ke Zhang is the Chief Scientific Officer and a member of the Board of Directors of SCG Cell Therapy. Before joining SCG, Dr. Zhang acted as the principal project leader at Janssen/Johnson & Johnson R&D and led a series of discovery and translational projects against chronic hepatitis B and HBV-related hepatocellular carcinoma. Dr. Zhang earned his Ph.D. in Molecular Medicine at the Faculty of Medicine, Technical University of Munich and received his postdoctoral training at the Institute of Medical Virology, Helmholtz Munich - German Research Center for Environmental Health.